news > tag > radiochemicals

Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation

David T. Drummond ⎜Mar 14, 2018 ⎜ Market

During the last decade, the utilization of 68Ga for the development of imaging agents has increased considerably with the leading position in the oncology. The imaging of infection and inflammation is lagging despite strong unmet medical needs. This review presents the potential routes for the development of 68Ga-based agents for the imaging and quantification of infection and inflammation in various diseases and connection of the diagnosis to the treatment for the individualized patient management.


The medical need for specific agents for noninvasive, quantitative, and whole-body imaging of inflammation and infection has not been met yet despite decades of research. However, the prerequisites in terms of identification of potential targets, design and synthesis of the respective ligands, and imaging technologies are evolving very fast. The potential of accurate and quantitative lesion localization as well as monitoring of the treatment response promises personalized patient management.

The use of 68Ga in oncology is established proving the strong potential of 68Ga for the promotion of PET technology for effective and efficient diagnostics and personalized medicine. The experience of oncological 68Ga-based agents is getting translated to inflammation and infection. Pretargeted imaging technology opens wide possibilities based on antibody biomarkers.

Contrast Media & Molecular Imaging
Volume 2018 (2018), Article ID 9713691, 24 pages

Copyright © 2018 Irina Velikyan

More about this article here:


Tumor-Killing Targeted Radiation PRRT Approved by U.S. FDA

David T. Drummond ⎜Feb 14, 2018 ⎜ Market

The first Peptide Receptor Radionuclide Therapy (PRRT) has received FDA approval. Lutetium 177 DOTA-TATE (Lu 177), a type of PRRT, is now approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors in adults.

FDA approval of PRRT using Lu-177 will allow more eligible U.S. patients to receive this “life extending” treatment. Lu-177 is manufactured by Advanced Accelerator Applications (AAA), a Novartis company. Prior to the FDA approval, PRRT with Lu-177 was only available in a limited number of American treatment centers as part of an expanded access program or through a clinical trial.

Click here to see full news release.


isoSolutions supplier IRE is proud to announce a partnership with ASML

David T. Drummond ⎜Feb 1, 2018 ⎜ Supplier

IRE is proud to announce a partnership with ASML to further develop a new, non-fission production method for medical isotopes such as Mo-99/Tc-99m. This partnership has resulted in the start of the LightHouse Isotopes BV, an ambitious initiative for the development of a promising alternative production method for a sustainable long term supply of Mo-99.

Click here to see full post.